Gold bars to be exempt from tariffs, White House clarifies
Investing.com -- Nutriband Inc. (NASDAQ:NTRB) stock rose 8% on Friday after the company announced that the U.S. Food and Drug Administration (FDA) has granted a Type C Meeting for its lead product, AVERSA FENTANYL, an abuse-deterrent fentanyl transdermal system.
The virtual face-to-face meeting, scheduled for September 18, 2025, will provide feedback on the Chemistry, Manufacturing, and Controls plans for the product from submission through approval and commercialization. The meeting will be held with the FDA’s Division of Anesthesiology, Addiction Medicine, and Pain Medicine.
Nutriband is developing the product in partnership with Kindeva, combining Nutriband’s AVERSA abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. The technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
If approved, AVERSA FENTANYL would be the world’s first abuse-deterrent opioid patch designed to deter misuse and reduce accidental exposure risks of transdermal fentanyl patches. The company estimates potential peak annual U.S. sales of $80 million to $200 million.
The AVERSA abuse deterrent technology is protected by patents in 46 countries, including the United States, Europe, Japan, and China. While initially focusing on the U.S. market, Nutriband aims to make the product available in all major medical markets worldwide.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.